Abingdon Health PLC
LSE:ABDX
Abingdon Health PLC
Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. The company is headquartered in York, North Yorkshire and currently employs 151 full-time employees. The company went IPO on 2020-12-15. The firm operates through three segments: Contract Development, Contract Manufacturing and Product Sales. The Contract Development segment comprises development work for third parties and is recognized over time based on a proportion of completion. The Contract Manufacturing segment comprises contract development and manufacturing activities. The Product Sales segment comprises the sale of ABC-19, pocket diagnostic products, progressive rod cone degeneration (PCRD) tests and antibodies for research use. Its products also include Seralite, which includes Free Light Chain (FLC) Serum. The Company’s geographical market include the United Kingdom, the United States/Canada, rest of world (ROW).
Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. The company is headquartered in York, North Yorkshire and currently employs 151 full-time employees. The company went IPO on 2020-12-15. The firm operates through three segments: Contract Development, Contract Manufacturing and Product Sales. The Contract Development segment comprises development work for third parties and is recognized over time based on a proportion of completion. The Contract Manufacturing segment comprises contract development and manufacturing activities. The Product Sales segment comprises the sale of ABC-19, pocket diagnostic products, progressive rod cone degeneration (PCRD) tests and antibodies for research use. Its products also include Seralite, which includes Free Light Chain (FLC) Serum. The Company’s geographical market include the United Kingdom, the United States/Canada, rest of world (ROW).
